Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.

S Slavin(N. I. Lobachevsky State University of Nizhny Novgorod), Reuven Or(Hadassah Academic College), Joseph Kapelushnik(Hadassah Medical Center), Elizabeth Naparstek(Hebrew University of Jerusalem), Arnon Nagler(Sheba Medical Center), Aliza Ackerstein(Hadassah Academic College)

PubMed

December 1, 1995

Cited by 213

Related Papers

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

|Blood|1998|1.9k

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

|Blood|1998|1.8k

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

|New England Journal of Medicine|2020|859

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

|Journal of Clinical Oncology|2013|439

Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation

|Blood|2010|430